AR064530A1 - Procedimientos para la administracion de vacunas - Google Patents

Procedimientos para la administracion de vacunas

Info

Publication number
AR064530A1
AR064530A1 ARP070105897A ARP070105897A AR064530A1 AR 064530 A1 AR064530 A1 AR 064530A1 AR P070105897 A ARP070105897 A AR P070105897A AR P070105897 A ARP070105897 A AR P070105897A AR 064530 A1 AR064530 A1 AR 064530A1
Authority
AR
Argentina
Prior art keywords
vaccine
canine
orally
viral antigens
dose
Prior art date
Application number
ARP070105897A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39609100&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR064530(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AR064530A1 publication Critical patent/AR064530A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/235—Adenoviridae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0225—Spirochetes, e.g. Treponema, Leptospira, Borrelia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/175—Canine distemper virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/23—Parvoviridae, e.g. feline panleukopenia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10071—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14071—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14311—Parvovirus, e.g. minute virus of mice
    • C12N2750/14334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18071—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18471—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Procedimiento de tratamiento de enfermedades caninas en perros que comprende la administracion de las cantidades de una vacuna terapéuticamente eficaces para el perro, en el que la vacuna comprende antígenos virales, una vacuna bacteriana o ambos, y en el que la vacuna se administra por vía subcutánea u oral segun los programas proporcionados en este documento. Reivindicacion 1: Una vacuna util para tratar enfermedades caninas en un perro donde la vacuna comprende cantidades terapéuticamente efectivas de antígenos virales, una vacuna bacteriana o ambos, y en el que la vacuna es formulada para ser administrada por vía cutánea u oral en una primera dosis, por vía oral en una segunda dosis, por vía oral en una tercera dosis opcional y por vía oral en una o más dosis anuales y, en el que los antígenos virales comprenden uno o más de 1) el virus de moquillo canino (MC), 2) el adenovirus canino de tipo 2 (AVC-2), 3) el virus de la parainfluenza canina (PIC), 4) el parvovirus canino (PVC) y 5) el coronavirus (CVC) y en el que la vacuna bacteriana comprende una o más bacterias seleccionadas entre Leptospira canicola, L, grippotyphosa, L. icterohaemorrhagiae, L. pomona, L. Bratislava y Bordetella bronchiseptica y cualquier combinacion de antígenos virales y bacterias de las mismas.
ARP070105897A 2006-12-27 2007-12-26 Procedimientos para la administracion de vacunas AR064530A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US87732206P 2006-12-27 2006-12-27

Publications (1)

Publication Number Publication Date
AR064530A1 true AR064530A1 (es) 2009-04-08

Family

ID=39609100

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070105897A AR064530A1 (es) 2006-12-27 2007-12-26 Procedimientos para la administracion de vacunas

Country Status (25)

Country Link
US (4) US20100028379A1 (es)
EP (5) EP2129392B1 (es)
JP (1) JP5762664B2 (es)
KR (1) KR101099883B1 (es)
CN (1) CN101573137B (es)
AR (1) AR064530A1 (es)
AU (1) AU2007343130C1 (es)
BR (1) BRPI0720667A8 (es)
CA (1) CA2674026C (es)
CY (1) CY1120015T1 (es)
DK (2) DK2762163T3 (es)
ES (2) ES2951660T3 (es)
FI (1) FI3300743T3 (es)
HK (4) HK1134243A1 (es)
HU (2) HUE036174T2 (es)
LT (1) LT2762163T (es)
MX (1) MX2009007087A (es)
NZ (1) NZ577855A (es)
PL (2) PL2762163T3 (es)
PT (1) PT2762163T (es)
SI (1) SI2762163T1 (es)
TR (1) TR201802917T4 (es)
TW (1) TW200833354A (es)
WO (1) WO2008084294A2 (es)
ZA (1) ZA200904756B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050089533A1 (en) * 2003-01-29 2005-04-28 Joseph Frantz Canine vaccines against Bordetella bronchiseptica
DK2762163T3 (en) * 2006-12-27 2018-02-12 Zoetis Services Llc PROCEDURE FOR VACCINE ADMINISTRATION
WO2009094006A2 (en) 2007-10-25 2009-07-30 Wake Forest University Health Sciences Bordetella outer-membrane protein antigens and methods of making and using the same
CN102655878A (zh) * 2009-07-17 2012-09-05 俄克拉荷马州大学评议会 舌上疫苗和施用器
US20110229516A1 (en) * 2010-03-18 2011-09-22 The Clorox Company Adjuvant phase inversion concentrated nanoemulsion compositions
CN101914502B (zh) * 2010-07-30 2012-01-11 中国农业科学院哈尔滨兽医研究所 Ⅰ型犬腺病毒弱毒疫苗株及其应用
US20120107354A1 (en) * 2010-10-30 2012-05-03 George Dacai Liu Viral vaccine and process for preparing the same
WO2012075379A2 (en) 2010-12-02 2012-06-07 Oncolytics Biotech Inc. Liquid viral formulations
AU2011336410B2 (en) 2010-12-02 2015-01-22 Oncolytics Biotech Inc. Lyophilized viral formulations
EP2695938B1 (en) 2011-03-17 2016-11-30 National UniversityCorporation Mie University Antibody production method
MX363510B (es) * 2012-05-31 2019-03-26 Zoetis Llc Vacuna con coronavirus respiratorio canino para proteccion contra infecciones de b. bronchiseptica.
CZ307883B6 (cs) * 2013-01-29 2019-07-24 Bioveta, A.S. Multivalentní vakcína k imunoprofylaxi infekčních onemocnění psů
CN107320720A (zh) * 2016-04-29 2017-11-07 普莱柯生物工程股份有限公司 一种疫苗组合物、试剂盒及应用
CN106591242B (zh) * 2016-11-18 2019-08-30 北京世纪元亨动物防疫技术有限公司 一株犬细小病毒毒株cpv-yh及其应用
MA47461A (fr) 2017-02-13 2019-12-18 Boehringer Ingelheim Animal Health Usa Inc Applicateur de liquide pour administrer des vaccins
GB201806460D0 (en) * 2018-04-20 2018-06-06 Secr Defence Pharmaceutical compositions and associated kits
WO2024121203A1 (en) * 2022-12-07 2024-06-13 Intervet International B.V. Vaccine for vaccinating a canine

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US5013663A (en) * 1983-06-15 1991-05-07 American Home Products Corporation Canine corona virus vaccine
SE8405493D0 (sv) 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
DE3526809A1 (de) * 1985-07-26 1987-04-02 Behringwerke Ag Tollwut-lebendimpfstoff
DK166762B1 (da) 1986-01-14 1993-07-12 Nederlanden Staat Fremgangsmaade til fremstilling af immunogenkomplekser og farmaceutisk sammensaetning indeholdende saadanne komplekser
US5019388A (en) * 1986-10-14 1991-05-28 Norden Laboratories Inc. Bordetella bronchiseptica vaccine
US5000951A (en) * 1987-03-09 1991-03-19 Diamond Scientific Company Multivalent canine distemper virus vaccine
US4990367A (en) * 1987-03-09 1991-02-05 Diamond Scientific Company Canine distemper virus vaccine
FR2652501B1 (fr) 1989-10-02 1992-01-10 Rhone Merieux Elements therapeutiques pour l'administration orale d'un medicament aux animaux et procede de fabrication.
US5178862A (en) * 1989-12-01 1993-01-12 Parhelion Corporation Canine distemper virus vaccine and method of preparation
US5757063A (en) * 1994-03-25 1998-05-26 Kabushiki Kaisha Toshiba Semiconductor device having an extrinsic gettering film
CN1117081A (zh) * 1995-03-16 1996-02-21 高云 犬瘟热狂犬病细小病毒三联活疫苗、毒种及制造方法
CN1137347A (zh) * 1995-06-22 1996-12-11 中国人民解放军第四军医大学 犬五联(犬狂犬、犬瘟热、犬细小病毒、犬腺病毒2型、犬副流感)活疫苗
AU4133397A (en) * 1996-10-28 1998-05-22 Pfizer Inc. Oral vaccines for young animals with an enteric coating
US5884583A (en) 1997-03-28 1999-03-23 Rhone Merieux, Inc. Field bag boost vaccination delivery system
US6867353B2 (en) 2000-02-12 2005-03-15 Exploregen Inc. Production method of recombinant rotavirus structural proteins and vaccine composition
MY128159A (en) * 2000-06-30 2007-01-31 Wyeth Corp Methods and composition for oral vaccination
US20030129161A1 (en) 2001-09-17 2003-07-10 Hsien-Jue Chu Interleukin-12 as a veterinary vaccine adjuvant
US20050089533A1 (en) * 2003-01-29 2005-04-28 Joseph Frantz Canine vaccines against Bordetella bronchiseptica
CA2513352C (en) * 2003-01-29 2010-10-12 Pfizer Products Inc. Canine vaccines against bordetella bronchiseptica
EP1778281A4 (en) 2004-06-21 2010-01-20 Merial Ltd VACCINATION OF SKUNKS AND / OR MUNGOS AGAINST TOLLWUT
WO2006014292A2 (en) 2004-07-02 2006-02-09 Dattwyler Raymond J Oral vaccine for borrelia
AU2006231916A1 (en) * 2005-04-07 2006-10-12 Pharmacia & Upjohn Company Llc Formulations and process for production of Bordetella bronchiseptica p68 antigen and vaccines
KR20110126726A (ko) * 2005-10-07 2011-11-23 화이자 프로덕츠 인코포레이티드 개과 동물의 인플루엔자의 치료를 위한 백신 및 방법
DK2762163T3 (en) * 2006-12-27 2018-02-12 Zoetis Services Llc PROCEDURE FOR VACCINE ADMINISTRATION

Also Published As

Publication number Publication date
BRPI0720667A8 (pt) 2017-04-25
EP4233899A3 (en) 2023-11-08
WO2008084294A2 (en) 2008-07-17
JP5762664B2 (ja) 2015-08-12
TR201802917T4 (tr) 2018-03-21
US11524068B2 (en) 2022-12-13
FI3300743T3 (fi) 2023-08-11
EP3300743A1 (en) 2018-04-04
CN101573137A (zh) 2009-11-04
EP2129392B1 (en) 2013-07-31
LT2762163T (lt) 2018-02-26
BRPI0720667A2 (pt) 2014-01-14
CA2674026C (en) 2018-08-21
HK1134243A1 (en) 2010-04-23
AU2007343130B2 (en) 2012-12-20
HK1200372A1 (en) 2015-08-07
JP2008169207A (ja) 2008-07-24
PL2762163T3 (pl) 2018-05-30
PL3300743T3 (pl) 2023-09-11
EP2762163A1 (en) 2014-08-06
EP2762163B1 (en) 2018-01-03
EP2129392A2 (en) 2009-12-09
HUE062920T2 (hu) 2023-12-28
US20200316192A1 (en) 2020-10-08
HUE036174T2 (hu) 2018-06-28
HK1249031A1 (zh) 2018-10-26
US20100028379A1 (en) 2010-02-04
KR20090094393A (ko) 2009-09-04
DK3300743T3 (da) 2023-07-24
AU2007343130A1 (en) 2008-07-17
EP2762162A1 (en) 2014-08-06
TW200833354A (en) 2008-08-16
PT2762163T (pt) 2018-02-22
NZ577855A (en) 2012-07-27
US20230078668A1 (en) 2023-03-16
AU2007343130C1 (en) 2017-11-09
DK2762163T3 (en) 2018-02-12
CY1120015T1 (el) 2018-12-12
CA2674026A1 (en) 2008-07-17
ZA200904756B (en) 2010-05-26
KR101099883B1 (ko) 2011-12-28
EP4233899A2 (en) 2023-08-30
ES2660035T3 (es) 2018-03-20
US20150182619A1 (en) 2015-07-02
MX2009007087A (es) 2009-08-12
HK1200374A1 (en) 2015-08-07
SI2762163T1 (en) 2018-05-31
ES2951660T3 (es) 2023-10-24
CN101573137B (zh) 2014-05-14
WO2008084294A3 (en) 2008-12-31
EP3300743B1 (en) 2023-06-14
US11524067B2 (en) 2022-12-13

Similar Documents

Publication Publication Date Title
AR064530A1 (es) Procedimientos para la administracion de vacunas
NO20053734L (no) Hundevaksine mor Bordetella Bronchiseptica.
AR007864A1 (es) Formula de vacuna porcina, su utilizacion y kit de vacunacion que la contiene.
LU92135I2 (fr) Vaccin comprenant les souches inactivées de Leptospira en particulier L.interrogans sérogroupe canicola L.interrogans sérogroupe Icterohaemorrhagiae L.interrogans sérogroupe Australis sérovar Bratislava et L.kirschneri sérogroupe Grippotyphosa
PE20040420A1 (es) Vacunas para enfermedades reproductivas del ganado
JP2015526450A5 (es)
ECSP088787A (es) Vacuna de mycoplasma hyopneumoniae
AR056566A1 (es) Vacunas y procedimientos para tratar la gripe canina
AR043892A1 (es) Metodos para prevenir enfermedades reproductivas en el ganado vacuno
RU2013117079A (ru) Вируса гриппа способ репликации в культуре
BR112014001409A2 (pt) métodos e composições para vacinação contra staphylococcus aureus
CL2013002219A1 (es) Composicion inmunogena que comprende bordetella bronchiseptica y un antigeno de pertactina aislado; y su uso para tratar o prevenir la infeccion por un patogeno respiratorio canino en un perro.
ES2676833T3 (es) Vacuna para proteger a un rumiante contra la neumonía causada por Pasteurella multocida
CY1113061T1 (el) Ανοσογονες συνθεσεις για θεραπεια και προληψη ζωικων μολυνσεων
Gingerich et al. A parainfluenza virus 5 (PIV5)-vectored intranasal vaccine for Lyme disease provides long-lasting protection against tick transmitted Borrelia burgdorferi in mice
RU2012143152A (ru) Способ защиты от заболеваний, вызываемых вторичными патогенами
RU2013135887A (ru) Композиции для комплекса респираторных заболеваний собак
Lascorz et al. Descriptive study of evolution experienced by users of mental health residence, after 10 years of operation
Gingerich et al. Intranasal vaccine for Lyme disease provides protection against tick transmitted Borrelia burgdorferi beyond one year
ES2839623T3 (es) Inactivación de virus por deslipidación
Silva Relatório Coleta CAPES 2019
Fox Molluscum contagiosum
ES2577716T3 (es) Vacuna viva avirulenta con un adyuvante contra Mycoplasma hyopneumoniae
Kaplan et al. Nonresolving Osteomyelitis of the Maxilla and Maxillary Sinus after Long-term Use of Oral Bisphosphonates
Lloret Feline panleukopenia: new challenges of an old disease.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal